Division contact information & address

Leiden chemists have proposed a new model for enzymatic reactions, in which the flexibility of the substrate is much more important than previously thought. Their results are paradigm-shifting and could have major implications for drug research and enzyme engineering. Publication in Angewandte Chemi…

Prematurely born neonates require, amongst others, pharmaceutical therapy. Dosing guidelines for these therapies are often based on data from term born neonates or older infants, while these are not necessarily similar to prematurely born neonates.

Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: L.H. Heitman

The division of BioTherapeutics consists of the former divisions Biopharmaceutics and Drug Delivery Technology.

Accurate prediction of the unbound drug concentration-time profile at the CNS target site is crucial for the assessment of the right drug concentration-effect relationship. PBPK models have supported the PK prediction of the CNS target sites and the translation of PK data between species and between…

Knowledge is everywhere at Leiden University. It is also accessible for those who do not study or work at the University.

The Repository from the Drug Disease Model Resources (DDMoRe) consortium provides a home to a collection of computational models of disease and drug action that have been used in pharmaceutical and/or academic research. This publically available open-access resource will make it easier for researchers…

Tackling key challenges of Chemical Biology and Medicinal Chemistry to aid drug discovery is one of the focus areas of Leiden University. To this end, the Leiden Early Drug Discovery & Development network (LED3) was established by the Leiden Institute of Chemistry (LIC), the Institute of Biology Leiden…

This dissertation contains four works during my PhD. Different biomaterials have been designed based on coiled-coil peptides. These biomaterials have a range of applications, inclusing drug delivery, cell sorting to cell-cell fusion.

The Quantitative Clinical Pharmacology group is led by Prof. Dr. Catherijne Knibbe. Her research group aims to define how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically ill patients. Through combining the statistical…

Gerard van Westen has been appointed full Professor or Artificial Intelligence and Medicinal Chemistry. This chair has been jointly created by the Leiden Academic Centre for Drug Research (LACDR) and the Leiden Institute of Chemistry (LIC) as part of SAILS, the university stimulus program in Artificial…

Laura Heitman of the Leiden Academic Center for Drug Research (LACDR) has been nominated for the Prix Galien Research Award. This important pharmaceutical prize honors young, prominent researchers whose scientific research is of great importance for fundamental or clinical drug research.

The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)genetic alterations in so-called driver genes.

Our educational programmes span the entire spectrum of pharmaceutical education, from training of the next generation drug researchers in the areas of drug design, drug action, and drug use to educating the pharmacists of the future.

Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…

Pharmacist-clinical pharmacologist Robert Rissmann has been appointed Professor of Translational Dermatology. This extraordinary professorship has been created jointly by the Leiden Academic Centre for Drug Research (LACDR) and the Centre for Human Drug Research (CHDR) to strengthen their partnership…

An overview of awards and prizes granted to our staff and students in 2018, as well as special appointments and royal distinctions.

Knowledge institutions in the Netherlands are to work together with the pharma and biotech industries to accelerate drug discovery and development. To bridge the ‘lab-to-life’ gap, Leiden University and the LUMC have, as coordinators of Academic Pharma, submitted an application to the National Growth…

As a student of Bio-Pharmaceutical Sciences, you have a strong interest in drug development: from the onset of diseases to the effects of individual drugs in the body. Is that true for you? Then, Bio-Pharmaceutical Sciences might be the right study programme for you!

Particles are omnipresent in biopharmaceutical products. In protein-based therapeutics such particles are generally associated with impurities, either derived from the drug product itself (e.g. protein aggregates), or from extrinsic contaminations (e.g. cellulose fibers).

At the Leiden Curious Minds Centre, our research focuses on the relationship of exploratory behaviour and discovery learning to curiosity and the way children regulate their behaviour and emotions. We want to improve our understanding of how children can and do become more and more the captain of their…

LUMC researchers are looking for factors that point to illness at an early stage.

The NEASQC project brings together academic experts and industrial end-users to investigate and develop a new breed of Quantum-enabled applications that can take advantage of NISQ (Noise Intermediate-Scale Quantum) systems in the near future. NEASQC is use-case driven, addressing practical problems…

Can we bring novel treatment options to the clinic for UM patients with liver metastases?

Parasitic worms and stomach bacteria suppress immune reactions such as allergic responses. Parasitologist Hermelijn Smits and lung specialist Christian Taube from the LUMC are trying to learn from these micro-organisms.

Health workers have always sought ways to fight disease in vulnerable groups in the population. It is now clear that such research also benefits more prosperous countries. African worm infections and innovative thermometers have shown Leiden researchers how to fight diseases of affluence and keep health…

Nature is a never-ending source of inspiration for the researchers at the Institute of Biology Leiden (IBL). Based on a better fundamental understanding of nature, they are able to seek solutions in the area of health and biodiversity. The theme of IBL is ‘Harnessing biodiversity for health.’

Many metalloenzymes that are key to bioenergetics are membrane enzymes, with canonical examples the complexes I, II, III and IV in the mitochondrial inner membrane. To study these enzymes in a native-like lipid membrane environment, we aim to develop novel bioelectrochemical techniques.

LUMC researchers are looking for factors that point to illness at an early stage.

Your tuition fee depends on a number of factors, such as your nationality and your previous Dutch higher-education qualifications.

When you apply for admission, you’ll be asked to submit several documents.

Get to know us through our online and in-person events for prospective students!

Your time at Leiden is about more than just studying. Some of your best experiences will stem from being a part of our lively and diverse student community, as well as from life in the beautiful city of Leiden.

Lecture

This thesis discusses the discovery potential of Intensity Frontier experiments.

Matthias Barz has been appointed full Professor of Biotherapeutics Delivery at the Leiden Academic Centre for Drug Research (LACDR).

Two directors. Both professors of mathematics, but one of them is a biologist. One comes, and the other goes. Roeland Merks will succeed Arjen Doelman as director of the Lorentz Center in September. What has been accomplished and what are the plans? And above all, what makes the Lorentz Center so un…

Streptomyces present a valuable platform for natural product discovery. Lugdunomycin is a novel angucycline-derived polyketide from Streptomyces sp QL37, with unprecedented skeleton and antimicrobial activity.

Vasiliki Kosta participated in the García Pelayo Seminar of the Center for Political and Constitutional Studies, Madrid entitled: ‘Discretionary Powers and Judicial Review: What Destiny for the Principle of Proportionality?’

Through metabolism, biochemical processes give rise to the complexity of life. Acquired and inborn errors in metabolism underlie many diseases occurring in man. The challenge for present day medical biochemistry is to find, and integrate, pieces of information at molecular, cell and organismal level…

Multiple Sclerosis, Parkinson’s and Alzheimer’s disease are the most common neurodegenerative disorders. Unfortunately, no effective treatments are currently available to halt the progression of these neuroinflammatory diseases [1].

Allosteric modulation has long been recognized as a general and widespread mechanism for the control of protein function. Modulators bind to regulatory sites distinct from the active site on the protein, resulting in conformational changes that may profoundly influence protein function. This concept…

What distinguishes a tumour cell from a healthy cell? Researchers are trying to answer this question as precisely as possible. Certain differences could eventually lead to new therapies.

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

Key publications of the Antiviral Pharmacology group.

The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.

Psychologist Bernadet Klaassens initiated a large fMRI study on the effect of drugs on brain networks in aging and Alzheimer's disease. It generated a unique data set and insight into a new method to develop drugs for patients with Alzheimer's.

PhD defence

Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.